Perimenopause Guidelines Compared: ADA, AACE, Endocrine Society, USPSTF, and NAMS
HealthRX.com
Guidelines back hormone therapy for bothersome symptoms
Key numbers
- 10 yearsNAMS: time since menopause onset for a favorable hormone therapy benefit-risk, if no contraindicationsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 12 monthsMonths in a row without a period needed to define menopause; perimenopause is the time leading up to itSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 60 daysSTRAW+10 late transition: gap without a period that marks the late perimenopause stageSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- NAMS 2022 / most effective for vasomotor symptoms and GSM [1]
- NAMS 2022 / favorable benefit-risk under 60 or within 10 years [1]
- Endocrine Society 2015 / benefits may exceed risks for most symptomatic women under 60 [2]
- USPSTF 2022 / D recommendation against hormone therapy for prevention [3]
- AACE 2017 / base hormone therapy on cardiovascular risk, age, time since menopause [4]
How is perimenopause defined?
Menopause is reached after 12 months in a row with no period, and perimenopause is the time leading up to it [9]. In the STRAW+10 staging system, the early transition (stage -2) is persistent variability of 7 or more days between consecutive cycle lengths, and the late transition (stage -1) is a gap of 60 days or longer without a period [9]. A random FSH above 25 IU/L is a criterion only for the late transition; AMH, inhibin B and antral follicle count are supportive only [9].
What does NAMS recommend?
NAMS says hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture [1]. For women younger than 60 or within 10 years of menopause onset with no contraindications, it calls the benefit-risk ratio favorable for bothersome vasomotor symptoms and prevention of bone loss [1]. Risks differ by type, dose, duration, route, timing and whether a progestogen is used; longer durations should be for documented indications such as persistent symptoms, with shared decision-making and periodic reevaluation [1].
NAMS's 2023 nonhormone statement predates elinzanetant's approval in October 2025 [6][7]. It recommends cognitive-behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin and fezolinetant, while not recommending supplements or herbal remedies [6].
What people on Reddit report
Reddit accounts from people told by a doctor whether hormone therapy was possible before menopause. They describe different experiences and suggest switching doctors.
My gynecologist told me that same thing: that there wasn't anything that she could do until it had been 12 months after my last period. It is outdated information and is no longer medically accurate.Read the source discussion
It's absolutely false that she can't get treatment until she's postmenopausal. She could be in peri for another 10 years and should not be expected to suffer that whole time.Read the source discussion
Dr Kameelah Phillips on why hormone therapy is now first line for hot flashes
Dr Phillips argues that hormone therapy has moved to the front of the line for treating perimenopause and menopause symptoms, especially hot flashes, night sweats, and mood and sleep problems. In her view, older advice to rely on antidepressants or simply exercise and cut back on wine was not very helpful, and hormones are now used mainstream. She explains that estrogen is the main hormone behind these symptoms, and that women should talk with their health care provider about estrogen and progesterone. She also says hormone therapy is not right for everyone, such as women with a personal history of breast cancer, blood clots, stroke, or liver disease, and that non-hormonal options exist for them.
Who is speaking?
Dr. Kameelah Phillips. Menopause specialist, as described in the video description Background
What does the Endocrine Society recommend?
The Endocrine Society says menopausal hormone therapy is the most effective treatment for vasomotor symptoms, and that benefits may exceed risks for most symptomatic postmenopausal women under 60 or under 10 years since menopause onset [2]. Current evidence does not justify using it to prevent coronary heart disease, breast cancer or dementia [2].
What does the USPSTF say?
The 2022 USPSTF statement gives combined estrogen and progestin (in women with an intact uterus), and estrogen alone (in women who have had a hysterectomy), a D recommendation for primary prevention of chronic conditions in postmenopausal persons [3]. Its population is asymptomatic postmenopausal persons considering hormone therapy for prevention [3].
What do AACE and the ADA say?
AACE's 2017 position statement updates its 2011 menopause guideline without replacing it [4]. It says hormone therapy in symptomatic postmenopausal women should be based on all cardiovascular risk factors, age and time since menopause [4]. It reiterates its earlier recommendation against bioidentical hormones [4]; FDA-approved estradiol and progesterone products are also available, while compounded bioidentical products are not FDA-approved [8].
The ADA Standards of Care chapter cited here covers diagnosis and classification of diabetes; it is a diabetes document, not a menopause guideline [5].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Questions worth asking
Frequently asked questions
Do NAMS and the Endocrine Society agree?
Does the USPSTF recommendation cover hot flashes?
Does AACE recommend compounded bioidentical hormones?
Does the ADA address perimenopause?
References
Show all 11 referencesHide references
- “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
- US Preventive Services Task Force, Mangione CM, Barry MJ, Nicholson WK, Cabana M, Caughey AB, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(17):1740-1746.
- Cobin RH, Goodman NF, AACE Reproductive Endocrinology Scientific Committee. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE. Endocr Pract. 2017;23(7):869-880.
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42.
- New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
- U.S. National Library of Medicine, DailyMed. Lynkuet elinzanetant prescribing information. Lynkuet elinzanetant label
- Menopause | FDA.
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012.
- Reddit participants. My 42yo girlfriend has perimeopause. She telling me doctor can't prescribe anything untill she has menopause (r/Menopause). Accessed 2026-11-10.
- CBS Mornings. What to know about new guidelines for menopause and perimenopause treatment. Accessed 2026-11-13.